What is CI stock price target for 2026?

WallStSmart's 12-month price target for Cigna Corp is $265.57, representing 8.6% downside from the current price of $290.58.

What is CI stock forecast?

Cigna Corp forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is CI undervalued based on price targets?

Our DCF intrinsic value for Cigna Corp is $1,358.34, against a current price of $290.58. The margin of safety is 78.61%.

Cigna Corp

NYSE: CI · HEALTHCARE · HEALTHCARE PLANS

$290.58

-0.60% today

Updated 2026-04-30

Market cap

$77.07B

P/E ratio

13.17

P/S ratio

0.28x

EPS (TTM)

$22.19

Dividend yield

2.12%

52W range

$237 – $343

Volume

1.7M

Market cap

$77.07B

P/E ratio

13.17

P/S ratio

0.28x

EPS (TTM)

$22.19

Dividend yield

2.12%

52W range

$237 – $343

Volume

1.7M

Cigna Corp (CI) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$290.58

Consensus

$350.36

+20.57%

2030 Target

$16,872.23

+5706.40%

DCF

$1,358.34

+78.61% MoS

Current price

$290.58

Analyst consensus

$350.36

+20.57%

2030 Target

$16,872.23

+5706.40%

Intrinsic (DCF)

$1,358.34

+78.61% MoS

14 analysts:

8 Buy1 Hold0 Sell

Management guidance

No specific CEO revenue targets found in available data. Brian Evanko succeeded David Cordani as CEO in March 2026. Management has not provided explicit multi-year revenue guidance through 2030 in disclosed materials.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$28,092.81

$363.9B Rev × 20x P/S

Base case (2030)

$16,872.23

$363.9B Rev × 12x P/S

Bear case (2030)

$11,248.15

$363.9B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$195.3B	$247.1B	$275.0B	$291.1B	$308.4B	$326.3B	$344.8B	$363.9B
Revenue growth	—	26.6%	11.3%	5.9%	5.9%	5.8%	5.7%	5.5%
EPS	$25.10	$27.34	$29.85	$31.24	$34.40	$37.85	$41.50	$45.30
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$13,481.24	$14,280.74	$15,107.81	$15,962.45	$16,872.23

Catalysts & risks

Growth catalysts

+ PBM reform and FTC settlement improving operational transparency and margins

+ Specialty pharmacy growth and Evernorth Health Services expansion

+ Leadership transition to Brian Evanko with potential strategic clarity

+ Medical membership stabilization after recent declines

+ Potential valuation multiple expansion as PBM headwinds clear

Key risks

- Express Scripts facing racketeering class-action lawsuit regarding rebate practices

- Regulatory scrutiny on PBM business model and pricing transparency

- Medical loss ratio pressure from increasing healthcare costs

- Potential legislation to break up integrated insurers (Mark Cuban endorsement of Break Up Big Medicine Act)

- CEO leadership transition execution risk during PBM transformation

- Declining medical membership trends in core insurance segments

Methodology

Cigna Corp's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.